{"gene":"IRF2","run_date":"2026-06-10T01:55:23","timeline":{"discoveries":[{"year":1989,"finding":"IRF2 was identified as a transcription factor that binds to the same regulatory cis-elements as IRF-1 within IFN and IFN-inducible gene promoters, but unlike IRF-1, functions as a transcriptional repressor/suppressor of IRF-1-mediated activation, establishing the competitive antagonism model.","method":"cDNA cloning, DNA binding assays, transcriptional reporter assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — original discovery paper with direct DNA binding and functional transcription assays, replicated extensively across subsequent studies","pmids":["2475256"],"is_preprint":false},{"year":1993,"finding":"IRF-1 and IRF-2 bind to virtually indistinguishable DNA recognition sequences (AAGTGA hexamer repeats) as determined by PCR-assisted DNA binding site selection; both factors occupy the same cis-elements in IFN-beta and IFN-inducible gene promoters.","method":"PCR-assisted DNA binding site selection (SELEX), EMSA","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — rigorous in vitro DNA binding determination, independently consistent with structural data","pmids":["7687740"],"is_preprint":false},{"year":1993,"finding":"Targeted disruption of IRF-2 in mice results in up-regulated type I IFN induction following NDV infection in fibroblasts, demonstrating that IRF-2 normally attenuates type I IFN gene expression in vivo; IRF-2-deficient mice also exhibit bone marrow suppression of hematopoiesis and B lymphopoiesis.","method":"Gene targeting in ES cells (knockout mice), virus infection assays, cellular phenotyping","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockout with defined molecular and cellular phenotypes, replicated by subsequent IRF-2 KO studies","pmids":["8402903"],"is_preprint":false},{"year":1994,"finding":"IRF-2 possesses a C-terminal transcriptional repression domain and a latent activation domain in its central region; repression by IRF-2 involves both competition with IRF-1 for promoter binding and active silencing of nearby activators via the repression domain.","method":"LexA fusion reporter assays, domain deletion/truncation analysis, transcriptional reporter assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — functional domain mapping with reporter assays in a single lab","pmids":["8152803"],"is_preprint":false},{"year":1994,"finding":"IRF-2 gene structure is located at chromosome 4q35.1 (human); the IRF-2 promoter contains an IRF binding site, and IRF-1 expression drives IRF-2 transcription, establishing an autoinhibitory regulatory loop within the IFN gene network.","method":"FISH chromosomal mapping, promoter deletion/reporter assays, stable and transient transfection","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter experiments plus chromosomal mapping, single lab","pmids":["7507207"],"is_preprint":false},{"year":1995,"finding":"IRF-2 (purified as HiNF-M, Mr ~48K) binds the cell-cycle element (CCE) of the human histone H4 gene FO108 and activates H4 transcription, establishing a direct link between IRF-2 and cell-cycle-regulated gene expression at the G1/S transition.","method":"Protein purification, EMSA, recombinant protein binding and transcriptional activation assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — protein purification with identity confirmation plus reconstituted transcriptional activation, independently validated in subsequent studies","pmids":["7566094"],"is_preprint":false},{"year":1995,"finding":"The oncogenic activity of IRF-2 maps to its N-terminal DNA binding/transcriptional repression domain (first ~160 amino acids), as C-terminal deletions retaining this domain are sufficient for NIH3T3 cell transformation and tumor formation in nude mice.","method":"C-terminal deletion mutants, focus formation assay, soft agar anchorage-independent growth, nude mouse tumor formation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain mapping with multiple functional transformation assays, single lab","pmids":["7630638"],"is_preprint":false},{"year":1998,"finding":"Cell-cycle-regulated transcription of histone H4 genes requires IRF-2; IRF-2-null fibroblasts lose stringent cell-cycle control and have reduced H4 mRNA levels, which are restored upon IRF-2 re-introduction, demonstrating that IRF-2 acts as an active transcriptional regulator (not merely a passive IRF-1 antagonist) in E2F-independent cell-cycle gene expression.","method":"IRF-2 knockout fibroblasts, synchronized cell cycle analysis, mRNA quantification, rescue by IRF-2 re-expression","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function plus rescue experiment with defined molecular phenotype, consistent with prior purification data","pmids":["9417064"],"is_preprint":false},{"year":1998,"finding":"The solution structure of the IRF-2 DNA-binding domain was determined by NMR: it is composed of a four-stranded antiparallel beta-sheet and three alpha-helices forming a winged helix-turn-helix (wHTH) fold; a long loop (Pro37-Asp51) and the second helix of the HTH motif contact the hexamer repeat DNA, defining IRF-2 as a novel subfamily of wHTH proteins.","method":"NMR spectroscopy with DNA binding perturbation analysis","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure with functional DNA contact mapping, single study","pmids":["9562558"],"is_preprint":false},{"year":1997,"finding":"IRF2 is phosphorylated exclusively on serine residues in vivo; in vitro, PKA, PKC, and CK2 phosphorylate IRF2 at multiple distinct sites, whereas MAP kinases (JNK1, p38, ERK2) do not.","method":"32P metabolic labeling, immunoprecipitation of HA-tagged IRF2, in vitro kinase assays, 2D phosphopeptide mapping, phosphoamino acid analysis","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct biochemical PTM characterization, single lab","pmids":["9213219"],"is_preprint":false},{"year":2000,"finding":"IRF-2-deficient mice develop an inflammatory skin disease involving CD8+ T cells that exhibit hyper-responsiveness and upregulated IFN-alpha/beta-induced genes; disease and CD8+ T cell abnormality are suppressed by nullizygosity of positive IFN-alpha/beta signaling regulators, establishing IRF-2 as a negative regulator of IFN-alpha/beta-induced transcription necessary for immune homeostasis.","method":"IRF-2 knockout mice, CD8+ T cell functional assays, genetic epistasis (IFNAR nullizygosity rescue)","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined cellular phenotype plus genetic epistasis rescue experiment","pmids":["11114377"],"is_preprint":false},{"year":2000,"finding":"IRF-2 deficiency results in compromised NK cell development (reduced numbers, immature phenotype) and defective Th1 differentiation in vivo; this phenotype cannot be compensated by IRF-1 alone, demonstrating that IRF-2 can act as a functional agonist of IRF-1 for a subset of ISRE-responsive genes.","method":"IRF-2 knockout mice, Leishmania major infection model, flow cytometric immune phenotyping","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined immune phenotypes and functional infection model","pmids":["10934221"],"is_preprint":false},{"year":2000,"finding":"IRF-2 functions as a negative regulator of the Cox-2 promoter: IRF-2-deficient macrophages show significantly increased basal and IFN-gamma-inducible Cox-2 expression; two IFN stimulation response elements in the mouse Cox-2 promoter bind endogenous IRF-2 and mediate repression.","method":"IRF-1/IRF-2 knockout macrophages, Cox-2 mRNA/protein quantification, EMSA, transient transfection reporter assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO macrophages combined with EMSA and promoter reporter assays with mutagenesis","pmids":["10859338"],"is_preprint":false},{"year":2002,"finding":"IFN-gamma suppresses IL-4 gene expression through IRF-1 and IRF-2; both factors induced by IFN-gamma bind to three distinct sites in the IL-4 promoter and function as transcriptional repressors of IL-4.","method":"EMSA, chromatin immunoprecipitation, promoter reporter assays, IRF-1/IRF-2 overexpression in T cells","journal":"Immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA and reporter assays demonstrating direct binding and repression, single lab","pmids":["12479817"],"is_preprint":false},{"year":2003,"finding":"IRF-2 (DNA binding domain alone) and IRF-1 can co-occupy the IRF-E of the CIITA type IV promoter; the IRF-2 DNA binding domain is sufficient for cooperative transactivation with IRF-1 at this promoter, while the latent activation domain is required for autonomous IRF-2 transactivation.","method":"EMSA off-rate assays, deletion mutant reporter assays, co-occupancy DNA binding experiments","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical binding and functional reporter assays, single lab","pmids":["12493643"],"is_preprint":false},{"year":2004,"finding":"Blimp-1, IRF-1, and IRF-2 bind with similar affinities to GAAAG-containing regulatory sites; Blimp-1, IRF-1, and IRF-2 all bind the IFN-beta promoter in vivo (by ChIP), and Blimp-1 inhibits IRF-1-dependent activation of IFN-beta promoter in cotransfections, suggesting competition with IRF-2 (and IRF-1) at shared sites.","method":"Binding competition assays, equilibrium dissociation constant measurement, ChIP, cotransfection reporter assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative binding assays plus in vivo ChIP, single lab","pmids":["15494505"],"is_preprint":false},{"year":2005,"finding":"IRF-2 autonomously and cell-intrinsically functions as a negative regulator of basophil expansion; IRF-2-deficient mice exhibit STAT6-independent basophil expansion, and reduced basophil numbers (via Kit mutation) abolish spontaneous Th2 polarization, placing IRF-2 upstream of basophil-mediated Th2 control.","method":"IRF-2 knockout mice, genetic epistasis with Kit mutation, in vitro Th1/Th2 differentiation assays, basophil depletion/neutralization","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse with genetic epistasis and multiple functional assays demonstrating cell-intrinsic mechanism","pmids":["15914553"],"is_preprint":false},{"year":2008,"finding":"IRF-2 physically interacts with RelA/p65 and recruits it into the nucleus; IRF-2 knockdown attenuates TNFα-induced NF-κB-dependent transcription by inhibiting nuclear localization of RelA, demonstrating that IRF-2 modulates NF-κB activity by controlling RelA subcellular localization.","method":"Co-immunoprecipitation, IRF-2 siRNA knockdown, NF-κB reporter assays, subcellular fractionation","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single Co-IP plus functional reporter and localization data, single lab","pmids":["18395009"],"is_preprint":false},{"year":2008,"finding":"IRF2 is sumoylated in vivo at three sites via the SUMO-E3 ligase PIASy; sumoylation does not affect IRF2 nuclear localization or DNA-binding activity, but increases its ability to repress IRF-1-mediated transcription and decreases its ability to activate ISRE and H4 promoters.","method":"Co-immunoprecipitation (IRF2/PIASy interaction), mutagenesis of sumoylation sites, in vivo sumoylation assay, reporter assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — sumoylation site mutagenesis with functional consequences, single lab","pmids":["18514056"],"is_preprint":false},{"year":2008,"finding":"IRF-2 is a substrate of Mdm2 E3-ubiquitin ligase requiring dual-site interaction: one binding site in IRF-2 contacts the Mdm2 hydrophobic pocket and a second requires the Mdm2 acid domain; mutation of either site attenuates IRF-2 ubiquitination, and the Mdm2/IRF-2 complex forms in cells.","method":"Co-immunoprecipitation (Mdm2/IRF-2 complex in cells), in vitro ubiquitination assays, site-directed mutagenesis of IRF-2 binding sites","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in vitro ubiquitination assay with mutagenesis plus cellular co-IP, single study","pmids":["19032150"],"is_preprint":false},{"year":2008,"finding":"IRF2 is required for homeostatic erythropoiesis: IRF2-null mice develop normocytic anemia with decreased late erythroblasts and increased apoptosis; this defect is rescued by additional knockout of IFNAR1, demonstrating that IRF2 maintains erythropoiesis by attenuating type I IFN signaling in erythroid progenitors.","method":"IRF-2 knockout mice, flow cytometric erythroid progenitor analysis, genetic epistasis (IFNAR1 double knockout rescue), apoptosis assays","journal":"Experimental hematology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined cellular phenotype plus genetic epistasis rescue","pmids":["18207304"],"is_preprint":false},{"year":2008,"finding":"IRF2-binding protein-1 (IRF2-BP1), which co-represses IRF2 transcriptional activity, also functions as a JDP2 ubiquitin E3 ligase via its RING-finger domain, enhancing JDP2 polyubiquitination and repressing ATF2-mediated transcription from CRE-containing promoters.","method":"Epitope-tag co-immunoprecipitation, in vitro ubiquitination assay, CRE reporter assays","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical ubiquitination assay and functional reporter assays, single lab","pmids":["18671972"],"is_preprint":false},{"year":2015,"finding":"IRF2 occupies TLR3 and other IFN-inducible gene promoters in the unstimulated state and maintains basal expression, open chromatin structure, and active histone modifications (H3K9/K14 acetylation, H3K4 trimethylation); IRF2 also directly interacts with the BAF chromatin remodeling complex to maintain this primed state, while IRF1 drives rapid transcriptional activation upon stimulation.","method":"ChIP-seq/ChIP assays for IRF1, IRF2, histone marks; Co-immunoprecipitation with BAF complex; gene expression in IRF2 KO cells","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus Co-IP with BAF plus KO phenotype, single lab","pmids":["25960866"],"is_preprint":false},{"year":2017,"finding":"IRF2 regulates the basal expression level of FAM111A transcriptionally; in a genome-wide siRNA screen, depletion of IRF2 enhanced replication of SPI-1-deleted orthopoxvirus, and this effect was found to be indirect through FAM111A (and the RFC complex), rather than direct antiviral activity by IRF2.","method":"Genome-wide siRNA screen, custom replication assays, microarray, quantitative RT-PCR, immunoblotting","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide screen with secondary validation and mechanistic follow-up, single lab","pmids":["28320935"],"is_preprint":false},{"year":2017,"finding":"HCFC2 is required for binding of both IRF1 and IRF2 to the Tlr3 promoter; HCFC2 mutations abolish macrophage responses to poly(I:C) and impair survival during viral infections, placing HCFC2 as a required co-factor for IRF2-dependent Tlr3 transcription.","method":"ENU mutagenesis screen, ChIP for IRF1/IRF2 at Tlr3 promoter, macrophage functional assays, infection survival studies","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic screen plus ChIP binding assay, single lab","pmids":["28970238"],"is_preprint":false},{"year":2019,"finding":"IRF2 directly binds a unique site in the GSDMD promoter to drive GSDMD transcription; IRF2-deficient macrophages show substantially reduced GSDMD expression, decreased IL-1β secretion, and inhibited pyroptosis; disruption of this single IRF2-binding site abolishes both canonical and non-canonical inflammasome signaling.","method":"ENU forward genetic screen, IRF2 KO macrophages, ChIP, promoter reporter assays with site-directed mutagenesis","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 2 / Strong — forward genetic screen identified IRF2, confirmed by KO with multiple orthogonal methods including ChIP and promoter mutagenesis","pmids":["31113851"],"is_preprint":false},{"year":2019,"finding":"IRF2 is identified by CRISPR genome-wide screen as required for caspase-4 expression and cytosolic LPS-mediated pyroptosis in human monocytes; IRF2 directly transcriptionally regulates caspase-4 (CASP4) levels; IFN-γ priming can compensate IRF2 deficiency through IRF1 induction.","method":"Genome-wide CRISPR/Cas9 screen, IRF2 KO in human monocytes and iPSC-derived monocytes, CASP4 expression analysis, bacterial infection assays","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide unbiased screen with orthogonal KO validation in multiple cell types","pmids":["31353801"],"is_preprint":false},{"year":2019,"finding":"IRF2 loss of function (identified by CRISPR screen) leads to reduced MHC class I antigen presentation by decreasing transcription of immunoproteasome components, TAP, and ERAP1, and simultaneously increases PD-L1 expression; IRF2 thus acts as a transcriptional activator of MHC-I pathway genes and a repressor of PD-L1.","method":"CRISPR forward genetic screen, IRF2 KO in HeLa and tumor cells, MHC-I antigen presentation assays, gene expression profiling","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — unbiased CRISPR screen plus mechanistic follow-up with multiple defined pathway readouts","pmids":["31471524"],"is_preprint":false},{"year":2019,"finding":"KRAS* represses IRF2 expression, which in turn directly represses CXCL3 transcription; KRAS*-mediated loss of IRF2 causes high CXCL3 expression that drives MDSC migration to tumors via CXCR2, promoting immune evasion.","method":"Enforced IRF2 expression rescue experiments, CXCR2 inhibition, tumor microenvironment immune cell analysis","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic axis validated by rescue (enforced IRF2 expression) and pharmacological inhibition, single lab","pmids":["30905761"],"is_preprint":false},{"year":2019,"finding":"IRF-2 overexpression down-regulates IFN-γ-induced PD-L1 promoter activity and protein levels in HCC cells in a dose-dependent manner; two functional IRF-1 response elements (IRE1 and IRE2) in the PD-L1 (CD274) promoter are bound by both IRF-1 and IRF-2, with IRF-2 antagonizing IRF-1-mediated PD-L1 activation.","method":"IRF-2 overexpression, PD-L1 promoter reporter assays, site-directed mutagenesis of IREs, IFN-γ stimulation assays","journal":"Cancer immunology, immunotherapy : CII","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter mutagenesis with functional reporter assays, single lab","pmids":["32377817"],"is_preprint":false},{"year":2019,"finding":"IRF2 is a master regulator of human keratinocyte stem cell fate: CRISPR knockdown of IRF2 in keratinocytes with low stem cell potential increases self-renewal, migration, and epidermis formation; IRF2 binds and regulates active cis-regulatory elements at interferon response and antigen presentation genes in keratinocytes.","method":"Chromatin profiling, transcriptional profiling, CRISPR-KD, keratinocyte functional assays (self-renewal, migration, epidermis formation)","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — integrated chromatin/transcriptional profiling plus CRISPR-KD with functional readouts, single lab","pmids":["31611556"],"is_preprint":false},{"year":2020,"finding":"Conditional deletion of Irf2 in intestinal epithelium causes premature differentiation of colonic stem cells (CoSCs) into transit-amplifying cells, reducing CoSC numbers and organoid-forming potential; this phenotype is phenocopied by repeated poly(I:C) injections in wild-type mice, demonstrating that IRF2 maintains colonic stem cell stemness by attenuating chronic type I IFN signaling.","method":"Conditional Irf2 knockout mice (Irf2ΔIEC), DSS colitis model, organoid assays, poly(I:C) injection epistasis","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with defined stem cell phenotype plus phenocopy by IFN induction establishing the mechanism","pmids":["32901054"],"is_preprint":false},{"year":2021,"finding":"IRF2 directly binds the GSDMD promoter to drive GSDMD transcription in cardiomyocytes; IRF2 silencing in hypoxia-treated H9c2 cells decreases GSDMD, GSDMD-N, and cleaved caspase-1 levels and reduces IL-1β and IL-18, confirming IRF2 as a transcriptional regulator of pyroptosis in myocardial infarction.","method":"Chromatin immunoprecipitation, dual luciferase reporter assay, IRF2 siRNA knockdown in H9c2 cells, in vivo MI model with IRF2 silencing","journal":"Molecular medicine reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assay confirming direct GSDMD promoter binding, consistent with PMID 31113851, single lab","pmids":["34878155"],"is_preprint":false},{"year":2021,"finding":"IRF2 directly transcriptionally activates CENP-N expression in NPC cells (confirmed by ChIP and dual luciferase assays); the IRF2/CENP-N/AKT axis promotes aerobic glycolysis, proliferation, cell cycling, and apoptosis resistance; CENP-N forms a complex with AKT (confirmed by immunoprecipitation and GST pulldown).","method":"ChIP, dual luciferase reporter assay, immunoprecipitation, GST pulldown, CENP-N KD/OE with phenotypic assays","journal":"Journal of experimental & clinical cancer research : CR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding confirmed by ChIP and reporter assay plus protein complex by pulldown, single lab","pmids":["34893086"],"is_preprint":false},{"year":2021,"finding":"IRF2 transcriptionally activates INPP4B in AML cells by binding its promoter; IRF2-driven INPP4B expression promotes autophagy and suppresses apoptosis; restoration of INPP4B blocks the pro-apoptotic effects of IRF2 knockdown.","method":"IRF2 overexpression/knockdown, INPP4B rescue experiments, autophagy markers (LC3-I/II, Beclin-1, p62), colony formation, apoptosis assays","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic rescue experiments establishing epistatic relationship, single lab","pmids":["28579269"],"is_preprint":false},{"year":2022,"finding":"CD8+ T cell-specific deletion of IRF2 prevents acquisition of the T cell exhaustion transcriptional program within tumors, enabling sustained effector functions; sustained antitumor control by IRF2-deficient CD8+ T cells requires continuous integration of both type I and type II IFN signals, establishing IRF2 as a feedback molecule that converts IFN signals into T cell suppression.","method":"CD8+ T cell-specific IRF2 conditional knockout, tumor models, adoptive cell therapy, immune checkpoint therapy, transcriptional profiling","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional KO with mechanistic IFN epistasis experiments and multiple functional readouts","pmids":["36370712"],"is_preprint":false},{"year":2023,"finding":"IRF2 is required cell-intrinsically for development of Ly6Clo (nonclassical) monocytes; NOTCH2/DLL1-induced transition of Ly6Chi to Ly6Clo monocytes requires IRF2, placing IRF2 downstream of NOTCH2 in a transcriptional hierarchy controlling nonclassical monocyte fate.","method":"IRF2 conditional deletion in myeloid progenitors, in vitro DLL1-induced monocyte transition assay, genetic epistasis with BCL6 and NUR77","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined developmental phenotype and in vitro epistasis, single lab","pmids":["37607223"],"is_preprint":false}],"current_model":"IRF2 is a winged helix-turn-helix transcription factor that binds AAGTGA hexamer repeats in IFN and IFN-inducible gene promoters using its N-terminal DNA-binding domain, where it predominantly acts as a transcriptional repressor by competing with the activator IRF1 and exerting silencing via a C-terminal repression domain; it is regulated post-translationally by phosphorylation (by PKA, PKC, CK2), sumoylation (by PIASy, increasing repressor activity), and ubiquitination (by Mdm2, requiring dual-site docking); beyond repressing IFN-stimulated genes, IRF2 directly activates transcription of GSDMD and CASP4 (enabling pyroptosis), histone H4 genes (linking it to cell-cycle progression at G1/S), MHC-I pathway components, and INPP4B; it attenuates type I IFN signaling to maintain erythroid, hematopoietic, intestinal epithelial, and keratinocyte stem cell homeostasis; recruits RelA/p65 to the nucleus to modulate NF-κB activity; cooperates with HCFC2 and the BAF chromatin remodeling complex for chromatin-level regulation of IFN-inducible promoters; and in CD8+ T cells, redirects sustained IFN signals into an exhaustion program that suppresses antitumor immunity."},"narrative":{"mechanistic_narrative":"IRF2 is a winged helix-turn-helix transcription factor that binds AAGTGA hexamer repeats in interferon (IFN) and IFN-inducible gene promoters, where its founding role is to antagonize the activator IRF-1 at shared cis-elements both by competitive occupancy and by active silencing through a C-terminal repression domain [PMID:2475256, PMID:7687740, PMID:8152803, PMID:9562558]. As an in vivo negative regulator of type I IFN gene induction, IRF2 restrains IFN-alpha/beta-driven transcription to preserve tissue homeostasis: its loss causes hematopoietic and B-lymphopoietic suppression, normocytic anemia, CD8+ T cell hyper-responsiveness and inflammatory skin disease, and depletion of colonic and keratinocyte stem cell pools — phenotypes rescued or phenocopied by manipulating IFN signaling [PMID:8402903, PMID:11114377, PMID:18207304, PMID:31611556, PMID:32901054]. IRF2 is not merely a passive antagonist: it acts as a direct transcriptional activator of histone H4 genes at the G1/S transition, controlling cell-cycle-regulated gene expression [PMID:7566094, PMID:9417064], and directly drives transcription of the pyroptosis effectors GSDMD and caspase-4 (CASP4), licensing canonical and non-canonical inflammasome signaling and IL-1beta release [PMID:31113851, PMID:31353801, PMID:34878155]. It also activates the MHC class I antigen-presentation machinery (immunoproteasome components, TAP, ERAP1) while repressing PD-L1, coupling IRF2 to tumor immune visibility [PMID:31471524, PMID:32377817]. IRF2 maintains a primed chromatin state at IFN-inducible promoters such as TLR3 — sustaining basal expression, open chromatin, and active histone marks — through cooperation with the BAF remodeling complex and the cofactor HCFC2 [PMID:25960866, PMID:28970238]. In CD8+ T cells, IRF2 converts sustained type I and type II IFN signals into an exhaustion program, and its deletion preserves effector function and antitumor control [PMID:36370712]. IRF2 activity is tuned post-translationally by serine phosphorylation (PKA, PKC, CK2), PIASy-mediated sumoylation that enhances repressor and weakens activator function, and Mdm2-dependent ubiquitination requiring dual-site docking [PMID:9213219, PMID:18514056, PMID:19032150].","teleology":[{"year":1989,"claim":"Established the foundational identity of IRF2: a transcription factor sharing IRF-1's DNA targets but opposing its activity, defining the competitive antagonism model that frames all later work.","evidence":"cDNA cloning with DNA-binding and transcriptional reporter assays","pmids":["2475256"],"confidence":"High","gaps":["Did not define the structural basis of binding or the domain mediating repression","Did not address in vivo physiological role"]},{"year":1993,"claim":"Resolved whether the antagonism arises from shared DNA recognition by showing IRF-1 and IRF-2 select indistinguishable AAGTGA hexamer repeats, and demonstrated in vivo that IRF-2 normally attenuates type I IFN induction.","evidence":"SELEX/EMSA binding-site selection plus IRF-2 knockout mice with NDV infection and hematopoietic phenotyping","pmids":["7687740","8402903"],"confidence":"High","gaps":["Did not explain how identical binding produces opposite transcriptional outputs","Hematopoietic suppression mechanism not yet tied to IFN signaling"]},{"year":1994,"claim":"Mapped the molecular basis of repression to a discrete C-terminal repression domain plus a latent central activation domain, and identified an IRF-1-driven autoregulatory loop controlling IRF-2 expression.","evidence":"LexA fusion reporters, truncation analysis, promoter deletion/reporter assays, FISH mapping","pmids":["8152803","7507207"],"confidence":"Medium","gaps":["Single-lab domain mapping","Identity of silencing partners recruited by the repression domain unknown"]},{"year":1995,"claim":"Reframed IRF2 as a bona fide activator, not just an antagonist, by purifying it as the histone H4 cell-cycle-element factor HiNF-M and showing direct activation of H4 transcription, and located its oncogenic activity to the N-terminal DNA-binding/repression domain.","evidence":"Protein purification, EMSA, reconstituted activation assays; deletion mutants with focus formation and nude mouse tumor assays","pmids":["7566094","7630638"],"confidence":"High","gaps":["How a single domain mediates both repression and transformation not resolved","Activator vs repressor context-switch not mechanistically defined"]},{"year":1997,"claim":"Began defining post-translational control of IRF2 by showing it is phosphorylated on serines by PKA, PKC, and CK2 but not MAP kinases.","evidence":"32P metabolic labeling, in vitro kinase assays, 2D phosphopeptide and phosphoamino acid analysis","pmids":["9213219"],"confidence":"Medium","gaps":["Functional consequence of phosphorylation on activity not established","Single-lab characterization"]},{"year":1998,"claim":"Solidified IRF2 as an active cell-cycle regulator via knockout-plus-rescue showing it is required for cell-cycle-regulated H4 transcription, and defined its fold as a winged helix-turn-helix making the structural basis of hexamer recognition explicit.","evidence":"IRF-2 KO fibroblasts with synchronized cell-cycle analysis and re-expression rescue; NMR structure with DNA-contact mapping","pmids":["9417064","9562558"],"confidence":"High","gaps":["Structure of full-length protein or DNA co-complex not determined","E2F-independent regulatory logic incompletely defined"]},{"year":2000,"claim":"Connected IRF2 loss-of-function phenotypes directly to dysregulated IFN-alpha/beta signaling through epistasis, and revealed context-dependent agonist behavior, while extending its repressor reach to the Cox-2 promoter.","evidence":"IRF-2 KO mice with IFNAR nullizygosity rescue; Leishmania infection model and NK/Th1 phenotyping; KO macrophages with EMSA and Cox-2 promoter reporters","pmids":["11114377","10934221","10859338"],"confidence":"High","gaps":["Determinants of agonist vs antagonist switching not defined","Direct vs indirect targets in immune cells not fully separated"]},{"year":2002,"claim":"Extended IRF2-mediated repression to T-helper cytokine control, showing IRF-1 and IRF-2 repress the IL-4 promoter downstream of IFN-gamma.","evidence":"EMSA, ChIP, promoter reporters with IRF overexpression in T cells","pmids":["12479817"],"confidence":"Medium","gaps":["Single-lab evidence","Relative contribution of IRF-1 versus IRF-2 not resolved"]},{"year":2003,"claim":"Defined how the IRF2 DNA-binding domain can cooperate with IRF-1, showing co-occupancy and DBD-sufficient cooperative transactivation at CIITA while autonomous activation requires the latent activation domain.","evidence":"EMSA off-rate, co-occupancy binding, and deletion-mutant reporter assays","pmids":["12493643"],"confidence":"Medium","gaps":["Promoter features dictating cooperation vs competition unknown","Single-lab study"]},{"year":2004,"claim":"Placed IRF2 within a broader competition network at IFN-beta by showing Blimp-1 shares its GAAAG sites and competes for occupancy.","evidence":"Quantitative binding competition, ChIP, cotransfection reporters","pmids":["15494505"],"confidence":"Medium","gaps":["Direct IRF-2 vs Blimp-1 displacement not isolated","In vivo relevance not tested"]},{"year":2008,"claim":"Greatly expanded IRF2 regulation and partnerships: defined PIASy-dependent sumoylation enhancing repression, Mdm2-mediated ubiquitination requiring dual-site docking, physical recruitment of RelA/p65 to the nucleus, and a requirement for IRF2 in erythropoiesis via IFN-signaling attenuation.","evidence":"Co-IP, in vivo sumoylation and site mutagenesis, in vitro ubiquitination with mutagenesis, siRNA with NF-kB reporters/fractionation, KO mice with IFNAR1 double-knockout rescue","pmids":["18514056","19032150","18395009","18207304","18671972"],"confidence":"High","gaps":["RelA recruitment rests on single Co-IP without reciprocal validation","How PTMs are integrated to set activator/repressor balance unresolved"]},{"year":2015,"claim":"Defined the chromatin-level mechanism of IRF2 priming: it occupies IFN-inducible promoters in the resting state, maintains open chromatin and active histone marks, and physically engages the BAF remodeling complex.","evidence":"ChIP/ChIP-seq for IRF1/IRF2 and histone marks, Co-IP with BAF, IRF2 KO expression analysis","pmids":["25960866"],"confidence":"Medium","gaps":["BAF interaction not reciprocally validated","Single-lab study"]},{"year":2017,"claim":"Identified a required cofactor (HCFC2) for IRF2 promoter binding at Tlr3 and showed an antiviral phenotype that is indirect, acting through transcriptional control of FAM111A rather than intrinsic IRF2 antiviral activity.","evidence":"ENU and genome-wide siRNA screens with ChIP, replication assays, and expression analysis","pmids":["28970238","28320935"],"confidence":"Medium","gaps":["Biochemical nature of the IRF2-HCFC2 interaction not defined","Direct vs indirect target distinction relies on a single screen lineage"]},{"year":2019,"claim":"Established IRF2 as a direct transcriptional activator of multiple effector programs identified by unbiased screens: GSDMD and CASP4 for pyroptosis, the MHC-I antigen-presentation machinery with PD-L1 repression, and stem-cell/tumor-microenvironment control via keratinocyte fate and the KRAS*-IRF2-CXCL3 axis.","evidence":"ENU and CRISPR forward genetic screens, KO in macrophages/monocytes/HeLa/tumor cells, ChIP and promoter mutagenesis, chromatin/transcriptional profiling, rescue and CXCR2 inhibition","pmids":["31113851","31353801","31471524","30905761","31611556","32377817"],"confidence":"High","gaps":["Mechanism selecting activation vs repression at each target promoter not defined","Cofactor requirements for direct activation incompletely mapped"]},{"year":2020,"claim":"Demonstrated in vivo that IRF2 maintains colonic stem cell stemness specifically by buffering chronic type I IFN signaling, with conditional deletion phenocopied by poly(I:C).","evidence":"Intestinal-epithelium conditional Irf2 KO, organoid assays, DSS colitis, poly(I:C) phenocopy","pmids":["32901054"],"confidence":"High","gaps":["Direct IRF2 target genes in stem cells not enumerated","Single-lab study"]},{"year":2021,"claim":"Broadened IRF2's direct activator repertoire to additional disease-relevant targets, confirming GSDMD-driven cardiomyocyte pyroptosis and identifying CENP-N (in NPC) and INPP4B (in AML) as direct transcriptional targets driving proliferation, glycolysis, autophagy, and apoptosis resistance.","evidence":"ChIP, dual-luciferase reporters, knockdown/overexpression and rescue with phenotypic assays in cardiomyocyte, NPC, and AML models","pmids":["34878155","34893086","28579269"],"confidence":"Medium","gaps":["Each axis validated in a single lab/cell context","Tissue-specificity of target selection not explained"]},{"year":2022,"claim":"Defined IRF2 as the feedback molecule that converts sustained type I and II IFN signaling into the CD8+ T cell exhaustion program, with cell-intrinsic deletion preserving effector function and antitumor control.","evidence":"CD8+ T cell-specific conditional KO, tumor and adoptive-transfer models, checkpoint therapy, IFN epistasis, transcriptional profiling","pmids":["36370712"],"confidence":"High","gaps":["Direct exhaustion-program target genes bound by IRF2 not fully mapped","Translational relevance to human T cells not established"]},{"year":2023,"claim":"Positioned IRF2 in a developmental transcriptional hierarchy by showing it is required cell-intrinsically downstream of NOTCH2 for nonclassical Ly6Clo monocyte differentiation.","evidence":"Myeloid-progenitor conditional deletion, DLL1-induced transition assay, epistasis with BCL6 and NUR77","pmids":["37607223"],"confidence":"Medium","gaps":["Direct IRF2 targets in the NOTCH2 pathway unknown","Single-lab study"]},{"year":null,"claim":"What molecular features at a given promoter switch IRF2 between active repressor and direct activator, and how its PTM code (phosphorylation, sumoylation, ubiquitination) integrates with cofactors (BAF, HCFC2) to set this balance, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking PTM state to activator/repressor switching","No structure of IRF2 in complex with cofactors or at activated vs repressed promoters","Determinants of tissue-specific target gene selection unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,3,5,25,26,27]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,8]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[8]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[17,18]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[22]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,10,25,26,27,35]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,3,5,25,27]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[5,7]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[25,26,32]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[22]}],"complexes":[],"partners":["IRF1","RELA","MDM2","PIAS4","HCFC2","SMARCA4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P14316","full_name":"Interferon regulatory factor 2","aliases":[],"length_aa":349,"mass_kda":39.4,"function":"DNA-binding transcription factor that specifically binds to the upstream regulatory region of type I interferon (IFN) and IFN-inducible genes and regulates their expression (PubMed:39013473, PubMed:7687740). Mainly acts as a transcription repressor, repressing expression (PubMed:39013473). Also acts as an activator for several genes including H4 and IL7 (PubMed:15226432, PubMed:9540062). Constitutively binds to the ISRE promoter to activate IL7 (PubMed:15226432). Involved in cell cycle regulation through binding the site II (HiNF-M) promoter region of H4 and activating transcription during cell growth (PubMed:9540062). Antagonizes IRF1 transcriptional activation (By similarity) Unable to bind to IRF2BP1 and IRF2BP2 corepressors and cannot mediate repression","subcellular_location":"Nucleus; Chromosome","url":"https://www.uniprot.org/uniprotkb/P14316/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IRF2","classification":"Not Classified","n_dependent_lines":56,"n_total_lines":1208,"dependency_fraction":0.046357615894039736},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IRF2","total_profiled":1310},"omim":[{"mim_id":"621243","title":"TRANSCRIPTION ACTIVATION SUPPRESSOR FAMILY, MEMBER 2; TASOR2","url":"https://www.omim.org/entry/621243"},{"mim_id":"615332","title":"INTERFERON REGULATORY FACTOR 2-BINDING PROTEIN 2; IRF2BP2","url":"https://www.omim.org/entry/615332"},{"mim_id":"615331","title":"INTERFERON REGULATORY FACTOR 2-BINDING PROTEIN 1; IRF2BP1","url":"https://www.omim.org/entry/615331"},{"mim_id":"608657","title":"JUN DIMERIZATION PROTEIN 2; JDP2","url":"https://www.omim.org/entry/608657"},{"mim_id":"605402","title":"CD274 MOLECULE; CD274","url":"https://www.omim.org/entry/605402"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Cell Junctions","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/IRF2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P14316","domains":[{"cath_id":"1.10.10.10","chopping":"7-110","consensus_level":"high","plddt":94.1486,"start":7,"end":110}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P14316","model_url":"https://alphafold.ebi.ac.uk/files/AF-P14316-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P14316-F1-predicted_aligned_error_v6.png","plddt_mean":63.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IRF2","jax_strain_url":"https://www.jax.org/strain/search?query=IRF2"},"sequence":{"accession":"P14316","fasta_url":"https://rest.uniprot.org/uniprotkb/P14316.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P14316/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P14316"}},"corpus_meta":[{"pmid":"2475256","id":"PMC_2475256","title":"Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes.","date":"1989","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2475256","citation_count":903,"is_preprint":false},{"pmid":"8402903","id":"PMC_8402903","title":"Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8402903","citation_count":584,"is_preprint":false},{"pmid":"30905761","id":"PMC_30905761","title":"KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.","date":"2019","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/30905761","citation_count":517,"is_preprint":false},{"pmid":"7687740","id":"PMC_7687740","title":"Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7687740","citation_count":404,"is_preprint":false},{"pmid":"2208287","id":"PMC_2208287","title":"Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated.","date":"1990","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2208287","citation_count":356,"is_preprint":false},{"pmid":"7507207","id":"PMC_7507207","title":"Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and IRF-2 genes: implications for a gene network in the interferon system.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7507207","citation_count":271,"is_preprint":false},{"pmid":"11114377","id":"PMC_11114377","title":"CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling.","date":"2000","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11114377","citation_count":207,"is_preprint":false},{"pmid":"7566094","id":"PMC_7566094","title":"Activation of a cell-cycle-regulated histone gene by the oncogenic transcription factor IRF-2.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7566094","citation_count":171,"is_preprint":false},{"pmid":"31113851","id":"PMC_31113851","title":"IRF2 transcriptionally induces GSDMD expression for pyroptosis.","date":"2019","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/31113851","citation_count":154,"is_preprint":false},{"pmid":"12479817","id":"PMC_12479817","title":"IFN-gamma represses IL-4 expression via IRF-1 and IRF-2.","date":"2002","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/12479817","citation_count":140,"is_preprint":false},{"pmid":"10934221","id":"PMC_10934221","title":"Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells.","date":"2000","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10934221","citation_count":136,"is_preprint":false},{"pmid":"24607843","id":"PMC_24607843","title":"Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24607843","citation_count":107,"is_preprint":false},{"pmid":"10859338","id":"PMC_10859338","title":"Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression.","date":"2000","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10859338","citation_count":107,"is_preprint":false},{"pmid":"28471447","id":"PMC_28471447","title":"MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/28471447","citation_count":105,"is_preprint":false},{"pmid":"15494505","id":"PMC_15494505","title":"B lymphocyte-induced maturation protein (Blimp)-1, IFN regulatory factor (IRF)-1, and IRF-2 can bind to the same regulatory sites.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15494505","citation_count":103,"is_preprint":false},{"pmid":"36370712","id":"PMC_36370712","title":"The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity.","date":"2022","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/36370712","citation_count":100,"is_preprint":false},{"pmid":"10415056","id":"PMC_10415056","title":"IL-12 is dysregulated in macrophages from IRF-1 and IRF-2 knockout mice.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10415056","citation_count":97,"is_preprint":false},{"pmid":"8152803","id":"PMC_8152803","title":"The oncogenic transcription factor IRF-2 possesses a transcriptional repression and a latent activation domain.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8152803","citation_count":87,"is_preprint":false},{"pmid":"32377817","id":"PMC_32377817","title":"Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.","date":"2020","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/32377817","citation_count":86,"is_preprint":false},{"pmid":"12543125","id":"PMC_12543125","title":"Cloning and expression analysis of rainbow trout Oncorhynchus mykiss interferon regulatory factor 1 and 2 (IRF-1 and IRF-2).","date":"2003","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12543125","citation_count":86,"is_preprint":false},{"pmid":"17363571","id":"PMC_17363571","title":"Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17363571","citation_count":85,"is_preprint":false},{"pmid":"15914553","id":"PMC_15914553","title":"Negative control of basophil expansion by IRF-2 critical for the regulation of Th1/Th2 balance.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15914553","citation_count":85,"is_preprint":false},{"pmid":"31471524","id":"PMC_31471524","title":"Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/31471524","citation_count":81,"is_preprint":false},{"pmid":"31353801","id":"PMC_31353801","title":"A genome-wide screen identifies IRF2 as a key regulator of caspase-4 in human cells.","date":"2019","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/31353801","citation_count":79,"is_preprint":false},{"pmid":"9417064","id":"PMC_9417064","title":"Cell cycle regulation of histone H4 gene transcription requires the oncogenic factor IRF-2.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9417064","citation_count":77,"is_preprint":false},{"pmid":"9001242","id":"PMC_9001242","title":"Constitutive activation of Epstein-Barr virus (EBV) nuclear antigen 1 gene transcription by IRF1 and IRF2 during restricted EBV latency.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9001242","citation_count":65,"is_preprint":false},{"pmid":"7822029","id":"PMC_7822029","title":"Differential expression of interferon regulatory factor 1 (IRF-1), IRF-2, and interferon consensus sequence binding protein genes in lipopolysaccharide (LPS)-responsive and LPS-hyporesponsive macrophages.","date":"1995","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/7822029","citation_count":65,"is_preprint":false},{"pmid":"31968218","id":"PMC_31968218","title":"Exosomes derived from human bone marrow mesenchymal stem cells transfer miR-222-3p to suppress acute myeloid leukemia cell proliferation by targeting IRF2/INPP4B.","date":"2020","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/31968218","citation_count":64,"is_preprint":false},{"pmid":"10321737","id":"PMC_10321737","title":"Activation and repression of the 2-5A synthetase and p21 gene promoters by IRF-1 and IRF-2.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10321737","citation_count":59,"is_preprint":false},{"pmid":"34893086","id":"PMC_34893086","title":"The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis.","date":"2021","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/34893086","citation_count":58,"is_preprint":false},{"pmid":"17475929","id":"PMC_17475929","title":"Pig conceptuses increase uterine interferon-regulatory factor 1 (IRF1), but restrict expression to stroma through estrogen-induced IRF2 in luminal epithelium.","date":"2007","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/17475929","citation_count":56,"is_preprint":false},{"pmid":"7630638","id":"PMC_7630638","title":"Transcription factor IRF-2 exerts its oncogenic phenotype through the DNA binding/transcription repression domain.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7630638","citation_count":53,"is_preprint":false},{"pmid":"26173586","id":"PMC_26173586","title":"MicroRNA-18a modulates P53 expression by targeting IRF2 in gastric cancer patients.","date":"2016","source":"Journal of gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/26173586","citation_count":47,"is_preprint":false},{"pmid":"18291530","id":"PMC_18291530","title":"Gene structures and promoter characteristics of interferon regulatory factor 1 (IRF-1), IRF-2 and IRF-7 from snakehead Channa argus.","date":"2008","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18291530","citation_count":47,"is_preprint":false},{"pmid":"16241857","id":"PMC_16241857","title":"Interferon regulatory factor 1 (IRF-1) and IRF-2 expression in breast cancer tissue microarrays.","date":"2005","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/16241857","citation_count":44,"is_preprint":false},{"pmid":"35212366","id":"PMC_35212366","title":"Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2.","date":"2022","source":"Journal of Crohn's & colitis","url":"https://pubmed.ncbi.nlm.nih.gov/35212366","citation_count":42,"is_preprint":false},{"pmid":"17059692","id":"PMC_17059692","title":"Transcriptional regulation of lipopolysaccharide (LPS)-induced Toll-like receptor (TLR) expression in murine macrophages: role of interferon regulatory factors 1 (IRF-1) and 2 (IRF-2).","date":"2006","source":"Journal of endotoxin research","url":"https://pubmed.ncbi.nlm.nih.gov/17059692","citation_count":42,"is_preprint":false},{"pmid":"25960866","id":"PMC_25960866","title":"Division of labor between IRF1 and IRF2 in regulating different stages of transcriptional activation in cellular antiviral activities.","date":"2015","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/25960866","citation_count":39,"is_preprint":false},{"pmid":"25463511","id":"PMC_25463511","title":"Ctenopharyngodon idella IRF2 plays an antagonistic role to IRF1 in transcriptional regulation of IFN and ISG genes.","date":"2014","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25463511","citation_count":38,"is_preprint":false},{"pmid":"30127908","id":"PMC_30127908","title":"miR-18a-5p promotes cell invasion and migration of osteosarcoma by directly targeting IRF2.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30127908","citation_count":37,"is_preprint":false},{"pmid":"22114555","id":"PMC_22114555","title":"A gammaherpesvirus cooperates with interferon-alpha/beta-induced IRF2 to halt viral replication, control reactivation, and minimize host lethality.","date":"2011","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/22114555","citation_count":37,"is_preprint":false},{"pmid":"33735820","id":"PMC_33735820","title":"IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin.","date":"2021","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33735820","citation_count":36,"is_preprint":false},{"pmid":"19032150","id":"PMC_19032150","title":"Role of Mdm2 acid domain interactions in recognition and ubiquitination of the transcription factor IRF-2.","date":"2009","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/19032150","citation_count":35,"is_preprint":false},{"pmid":"18395009","id":"PMC_18395009","title":"IRF-2 regulates NF-kappaB activity by modulating the subcellular localization of NF-kappaB.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18395009","citation_count":33,"is_preprint":false},{"pmid":"28320935","id":"PMC_28320935","title":"Triad of human cellular proteins, IRF2, FAM111A, and RFC3, restrict replication of orthopoxvirus SPI-1 host-range mutants.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28320935","citation_count":32,"is_preprint":false},{"pmid":"28512062","id":"PMC_28512062","title":"Hsa-miR-513b-5p suppresses cell proliferation and promotes P53 expression by targeting IRF2 in testicular embryonal carcinoma cells.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/28512062","citation_count":31,"is_preprint":false},{"pmid":"11721886","id":"PMC_11721886","title":"Mutation and association analysis of the interferon regulatory factor 2 gene (IRF2) with atopic dermatitis.","date":"2001","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11721886","citation_count":31,"is_preprint":false},{"pmid":"9540062","id":"PMC_9540062","title":"The integrated activities of IRF-2 (HiNF-M), CDP/cut (HiNF-D) and H4TF-2 (HiNF-P) regulate transcription of a cell cycle controlled human histone H4 gene: mechanistic differences between distinct H4 genes.","date":"1998","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/9540062","citation_count":30,"is_preprint":false},{"pmid":"21703300","id":"PMC_21703300","title":"Molecular cloning and characterization of interferon regulatory factor 1 (IRF-1), IRF-2 and IRF-5 in the chondrostean paddlefish Polyodon spathula and their phylogenetic importance in the Osteichthyes.","date":"2011","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21703300","citation_count":29,"is_preprint":false},{"pmid":"16871414","id":"PMC_16871414","title":"Gene structure and transcription of IRF-2 in the mandarin fish Siniperca chuatsi with the finding of alternative transcripts and microsatellite in the coding region.","date":"2006","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/16871414","citation_count":29,"is_preprint":false},{"pmid":"18514056","id":"PMC_18514056","title":"Regulation of IRF2 transcriptional activity by its sumoylation.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18514056","citation_count":28,"is_preprint":false},{"pmid":"14962090","id":"PMC_14962090","title":"Evaluation of the IRF-2 gene as a candidate for PSORS3.","date":"2004","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/14962090","citation_count":28,"is_preprint":false},{"pmid":"22119988","id":"PMC_22119988","title":"IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells.","date":"2011","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22119988","citation_count":28,"is_preprint":false},{"pmid":"19170204","id":"PMC_19170204","title":"Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer.","date":"2009","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19170204","citation_count":27,"is_preprint":false},{"pmid":"34878155","id":"PMC_34878155","title":"IRF2 contributes to myocardial infarction via regulation of GSDMD induced pyroptosis.","date":"2021","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/34878155","citation_count":26,"is_preprint":false},{"pmid":"34022918","id":"PMC_34022918","title":"LncRNA GAS5 modulates the progression of non-small cell lung cancer through repressing miR-221-3p and up-regulating IRF2.","date":"2021","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34022918","citation_count":25,"is_preprint":false},{"pmid":"32655783","id":"PMC_32655783","title":"LncRNA LINC00265/miR-485-5p/IRF2-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells.","date":"2020","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/32655783","citation_count":25,"is_preprint":false},{"pmid":"23422814","id":"PMC_23422814","title":"Molecular characterization of interferon regulatory factor 2 (IRF-2) homolog in pearl oyster Pinctada fucata.","date":"2013","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23422814","citation_count":25,"is_preprint":false},{"pmid":"12474233","id":"PMC_12474233","title":"Psoriatic lesional skin exhibits an aberrant expression pattern of interferon regulatory factor-2 (IRF-2).","date":"2003","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12474233","citation_count":25,"is_preprint":false},{"pmid":"30876449","id":"PMC_30876449","title":"IRF2-INPP4B-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells.","date":"2019","source":"Biological research","url":"https://pubmed.ncbi.nlm.nih.gov/30876449","citation_count":24,"is_preprint":false},{"pmid":"33264494","id":"PMC_33264494","title":"Circular RNA hsa_circ_0000658 inhibits osteosarcoma cell proliferation and migration via the miR-1227/IRF2 axis.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33264494","citation_count":24,"is_preprint":false},{"pmid":"27677680","id":"PMC_27677680","title":"Expression and functional characterization of interferon regulatory factors (irf2, irf7 and irf9) in the blunt snout bream (Megalobrama amblycephala).","date":"2016","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27677680","citation_count":24,"is_preprint":false},{"pmid":"28467773","id":"PMC_28467773","title":"miR-302b inhibits cancer-related inflammation by targeting ERBB4, IRF2 and CXCR4 in esophageal cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28467773","citation_count":24,"is_preprint":false},{"pmid":"18207304","id":"PMC_18207304","title":"Homeostatic erythropoiesis by the transcription factor IRF2 through attenuation of type I interferon signaling.","date":"2008","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/18207304","citation_count":23,"is_preprint":false},{"pmid":"12493643","id":"PMC_12493643","title":"The IRF-2 DNA binding domain facilitates the activation of the class II transactivator (CIITA) type IV promoter by IRF-1.","date":"2003","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12493643","citation_count":23,"is_preprint":false},{"pmid":"9562558","id":"PMC_9562558","title":"Solution structure of the IRF-2 DNA-binding domain: a novel subgroup of the winged helix-turn-helix family.","date":"1998","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/9562558","citation_count":23,"is_preprint":false},{"pmid":"17073600","id":"PMC_17073600","title":"The role of IRF1 and IRF2 transcription factors in leukaemogenesis.","date":"2006","source":"Current gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17073600","citation_count":22,"is_preprint":false},{"pmid":"25994869","id":"PMC_25994869","title":"Genetic association of key Th1/Th2 pathway candidate genes, IRF2, IL6, IFNGR2, STAT4 and IL4RA, with atopic asthma in the Indian population.","date":"2015","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25994869","citation_count":22,"is_preprint":false},{"pmid":"8475044","id":"PMC_8475044","title":"Characterization of the DNA binding domain of the mouse IRF-2 protein.","date":"1993","source":"Protein engineering","url":"https://pubmed.ncbi.nlm.nih.gov/8475044","citation_count":22,"is_preprint":false},{"pmid":"34992348","id":"PMC_34992348","title":"Downregulation of IRF2 Alleviates Sepsis-Related Acute Kidney Injury in vitro and in vivo.","date":"2021","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34992348","citation_count":21,"is_preprint":false},{"pmid":"11559933","id":"PMC_11559933","title":"Alterations in IRF1/IRF2 expression in acute myelogenous leukemia.","date":"2001","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/11559933","citation_count":20,"is_preprint":false},{"pmid":"28970238","id":"PMC_28970238","title":"HCFC2 is needed for IRF1- and IRF2-dependent Tlr3 transcription and for survival during viral infections.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28970238","citation_count":20,"is_preprint":false},{"pmid":"18671972","id":"PMC_18671972","title":"IRF2-binding protein-1 is a JDP2 ubiquitin ligase and an inhibitor of ATF2-dependent transcription.","date":"2008","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/18671972","citation_count":20,"is_preprint":false},{"pmid":"34185419","id":"PMC_34185419","title":"IRF2-mediated upregulation of lncRNA HHAS1 facilitates the osteogenic differentiation of bone marrow-derived mesenchymal stem cells by acting as a competing endogenous RNA.","date":"2021","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34185419","citation_count":20,"is_preprint":false},{"pmid":"9213219","id":"PMC_9213219","title":"Phosphorylation of the oncogenic transcription factor interferon regulatory factor 2 (IRF2) in vitro and in vivo.","date":"1997","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9213219","citation_count":20,"is_preprint":false},{"pmid":"20129639","id":"PMC_20129639","title":"Interferon regulatory factor (IRF)-2 activates the HPV-16 E6-E7 promoter in keratinocytes.","date":"2010","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/20129639","citation_count":20,"is_preprint":false},{"pmid":"31611556","id":"PMC_31611556","title":"IRF2 is a master regulator of human keratinocyte stem cell fate.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31611556","citation_count":19,"is_preprint":false},{"pmid":"28203525","id":"PMC_28203525","title":"MicroRNA-520c enhances cell proliferation, migration, and invasion by suppressing IRF2 in gastric cancer.","date":"2016","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/28203525","citation_count":19,"is_preprint":false},{"pmid":"29386090","id":"PMC_29386090","title":"[ARTICLE WITHDRAWN] MicroRNA-18a Targets IRF2 and CBX7 to Promote Cell Proliferation in Hepatocellular Carcinoma.","date":"2018","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/29386090","citation_count":19,"is_preprint":false},{"pmid":"18575764","id":"PMC_18575764","title":"siRNA targeting the IRF2 transcription factor inhibits leukaemic cell growth.","date":"2008","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18575764","citation_count":18,"is_preprint":false},{"pmid":"31350707","id":"PMC_31350707","title":"IRF-2 Inhibits Gastric Cancer Invasion and Migration by Down-Regulating MMP-1.","date":"2019","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31350707","citation_count":18,"is_preprint":false},{"pmid":"31934069","id":"PMC_31934069","title":"LncRNA XIST, as a ceRNA of miR-204, aggravates lipopolysaccharide-induced acute respiratory distress syndrome in mice by upregulating IRF2.","date":"2019","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31934069","citation_count":18,"is_preprint":false},{"pmid":"22042864","id":"PMC_22042864","title":"Characterization of dsRNA-induced pancreatitis model reveals the regulatory role of IFN regulatory factor 2 (Irf2) in trypsinogen5 gene transcription.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22042864","citation_count":18,"is_preprint":false},{"pmid":"31379068","id":"PMC_31379068","title":"IRF1 and IRF2 regulate the non-canonical inflammasome.","date":"2019","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/31379068","citation_count":17,"is_preprint":false},{"pmid":"33444646","id":"PMC_33444646","title":"IRF1 and IRF2 act as positive regulators in antiviral response of large yellow croaker (Larimichthys crocea) by induction of distinct subgroups of type I IFNs.","date":"2021","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33444646","citation_count":17,"is_preprint":false},{"pmid":"8713742","id":"PMC_8713742","title":"IRF-1 and IRF-2 as regulators of the interferon system and cell growth.","date":"1995","source":"Indian journal of biochemistry & biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/8713742","citation_count":17,"is_preprint":false},{"pmid":"23554911","id":"PMC_23554911","title":"Up-regulation of intestinal epithelial cell derived IL-7 expression by keratinocyte growth factor through STAT1/IRF-1, IRF-2 pathway.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23554911","citation_count":16,"is_preprint":false},{"pmid":"26545324","id":"PMC_26545324","title":"Fish IRF3 up-regulates the transcriptional level of IRF1, IRF2, IRF3 and IRF7 in CIK cells.","date":"2015","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26545324","citation_count":16,"is_preprint":false},{"pmid":"30017925","id":"PMC_30017925","title":"Regulation of IL-17 by lncRNA of IRF-2 in the pearl oyster.","date":"2018","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30017925","citation_count":16,"is_preprint":false},{"pmid":"16007130","id":"PMC_16007130","title":"A retroviral library genetic screen identifies IRF-2 as an inhibitor of N-ras-induced growth suppression in leukemic cells.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16007130","citation_count":16,"is_preprint":false},{"pmid":"28579269","id":"PMC_28579269","title":"IRF2-INPP4B axis participates in the development of acute myeloid leukemia by regulating cell growth and survival.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/28579269","citation_count":15,"is_preprint":false},{"pmid":"32901054","id":"PMC_32901054","title":"IRF2 maintains the stemness of colonic stem cells by limiting physiological stress from interferon.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32901054","citation_count":15,"is_preprint":false},{"pmid":"12537697","id":"PMC_12537697","title":"The role of the interferon regulatory factors, IRF-1 and IRF-2, in LPS-induced cyclooxygenase-2 (COX-2) expression in vivo and in vitro.","date":"2002","source":"Journal of endotoxin research","url":"https://pubmed.ncbi.nlm.nih.gov/12537697","citation_count":15,"is_preprint":false},{"pmid":"34930359","id":"PMC_34930359","title":"IRF2 inhibits ZIKV replication by promoting FAM111A expression to enhance the host restriction effect of RFC3.","date":"2021","source":"Virology journal","url":"https://pubmed.ncbi.nlm.nih.gov/34930359","citation_count":13,"is_preprint":false},{"pmid":"34423051","id":"PMC_34423051","title":"Propofol Ameliorates Microglia Activation by Targeting MicroRNA-221/222-IRF2 Axis.","date":"2021","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/34423051","citation_count":13,"is_preprint":false},{"pmid":"22773153","id":"PMC_22773153","title":"IRF-2 regulates B-cell proliferation and antibody production through distinct mechanisms.","date":"2012","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22773153","citation_count":13,"is_preprint":false},{"pmid":"10942060","id":"PMC_10942060","title":"The interferon-alpha regulation of interferon regulatory factor 1 (IRF-1) and IRF-2 has therapeutic implications in carcinoid tumors.","date":"2000","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/10942060","citation_count":13,"is_preprint":false},{"pmid":"19962964","id":"PMC_19962964","title":"SUMOylated IRF-1 shows oncogenic potential by mimicking IRF-2.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19962964","citation_count":13,"is_preprint":false},{"pmid":"37607223","id":"PMC_37607223","title":"Bcl6, Irf2, and Notch2 promote nonclassical monocyte development.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37607223","citation_count":12,"is_preprint":false},{"pmid":"36314827","id":"PMC_36314827","title":"IRF2 Cooperates with Phosphoprotein of Spring Viremia of Carp Virus to Suppress Antiviral Response in Zebrafish.","date":"2022","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/36314827","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50891,"output_tokens":8624,"usd":0.141016,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18473,"output_tokens":5864,"usd":0.119483,"stage2_stop_reason":"end_turn"},"total_usd":0.260499,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"IRF2 was identified as a transcription factor that binds to the same regulatory cis-elements as IRF-1 within IFN and IFN-inducible gene promoters, but unlike IRF-1, functions as a transcriptional repressor/suppressor of IRF-1-mediated activation, establishing the competitive antagonism model.\",\n      \"method\": \"cDNA cloning, DNA binding assays, transcriptional reporter assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — original discovery paper with direct DNA binding and functional transcription assays, replicated extensively across subsequent studies\",\n      \"pmids\": [\"2475256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"IRF-1 and IRF-2 bind to virtually indistinguishable DNA recognition sequences (AAGTGA hexamer repeats) as determined by PCR-assisted DNA binding site selection; both factors occupy the same cis-elements in IFN-beta and IFN-inducible gene promoters.\",\n      \"method\": \"PCR-assisted DNA binding site selection (SELEX), EMSA\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — rigorous in vitro DNA binding determination, independently consistent with structural data\",\n      \"pmids\": [\"7687740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Targeted disruption of IRF-2 in mice results in up-regulated type I IFN induction following NDV infection in fibroblasts, demonstrating that IRF-2 normally attenuates type I IFN gene expression in vivo; IRF-2-deficient mice also exhibit bone marrow suppression of hematopoiesis and B lymphopoiesis.\",\n      \"method\": \"Gene targeting in ES cells (knockout mice), virus infection assays, cellular phenotyping\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockout with defined molecular and cellular phenotypes, replicated by subsequent IRF-2 KO studies\",\n      \"pmids\": [\"8402903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"IRF-2 possesses a C-terminal transcriptional repression domain and a latent activation domain in its central region; repression by IRF-2 involves both competition with IRF-1 for promoter binding and active silencing of nearby activators via the repression domain.\",\n      \"method\": \"LexA fusion reporter assays, domain deletion/truncation analysis, transcriptional reporter assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — functional domain mapping with reporter assays in a single lab\",\n      \"pmids\": [\"8152803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"IRF-2 gene structure is located at chromosome 4q35.1 (human); the IRF-2 promoter contains an IRF binding site, and IRF-1 expression drives IRF-2 transcription, establishing an autoinhibitory regulatory loop within the IFN gene network.\",\n      \"method\": \"FISH chromosomal mapping, promoter deletion/reporter assays, stable and transient transfection\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter experiments plus chromosomal mapping, single lab\",\n      \"pmids\": [\"7507207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"IRF-2 (purified as HiNF-M, Mr ~48K) binds the cell-cycle element (CCE) of the human histone H4 gene FO108 and activates H4 transcription, establishing a direct link between IRF-2 and cell-cycle-regulated gene expression at the G1/S transition.\",\n      \"method\": \"Protein purification, EMSA, recombinant protein binding and transcriptional activation assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — protein purification with identity confirmation plus reconstituted transcriptional activation, independently validated in subsequent studies\",\n      \"pmids\": [\"7566094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The oncogenic activity of IRF-2 maps to its N-terminal DNA binding/transcriptional repression domain (first ~160 amino acids), as C-terminal deletions retaining this domain are sufficient for NIH3T3 cell transformation and tumor formation in nude mice.\",\n      \"method\": \"C-terminal deletion mutants, focus formation assay, soft agar anchorage-independent growth, nude mouse tumor formation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain mapping with multiple functional transformation assays, single lab\",\n      \"pmids\": [\"7630638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Cell-cycle-regulated transcription of histone H4 genes requires IRF-2; IRF-2-null fibroblasts lose stringent cell-cycle control and have reduced H4 mRNA levels, which are restored upon IRF-2 re-introduction, demonstrating that IRF-2 acts as an active transcriptional regulator (not merely a passive IRF-1 antagonist) in E2F-independent cell-cycle gene expression.\",\n      \"method\": \"IRF-2 knockout fibroblasts, synchronized cell cycle analysis, mRNA quantification, rescue by IRF-2 re-expression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function plus rescue experiment with defined molecular phenotype, consistent with prior purification data\",\n      \"pmids\": [\"9417064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The solution structure of the IRF-2 DNA-binding domain was determined by NMR: it is composed of a four-stranded antiparallel beta-sheet and three alpha-helices forming a winged helix-turn-helix (wHTH) fold; a long loop (Pro37-Asp51) and the second helix of the HTH motif contact the hexamer repeat DNA, defining IRF-2 as a novel subfamily of wHTH proteins.\",\n      \"method\": \"NMR spectroscopy with DNA binding perturbation analysis\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure with functional DNA contact mapping, single study\",\n      \"pmids\": [\"9562558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"IRF2 is phosphorylated exclusively on serine residues in vivo; in vitro, PKA, PKC, and CK2 phosphorylate IRF2 at multiple distinct sites, whereas MAP kinases (JNK1, p38, ERK2) do not.\",\n      \"method\": \"32P metabolic labeling, immunoprecipitation of HA-tagged IRF2, in vitro kinase assays, 2D phosphopeptide mapping, phosphoamino acid analysis\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct biochemical PTM characterization, single lab\",\n      \"pmids\": [\"9213219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"IRF-2-deficient mice develop an inflammatory skin disease involving CD8+ T cells that exhibit hyper-responsiveness and upregulated IFN-alpha/beta-induced genes; disease and CD8+ T cell abnormality are suppressed by nullizygosity of positive IFN-alpha/beta signaling regulators, establishing IRF-2 as a negative regulator of IFN-alpha/beta-induced transcription necessary for immune homeostasis.\",\n      \"method\": \"IRF-2 knockout mice, CD8+ T cell functional assays, genetic epistasis (IFNAR nullizygosity rescue)\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined cellular phenotype plus genetic epistasis rescue experiment\",\n      \"pmids\": [\"11114377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"IRF-2 deficiency results in compromised NK cell development (reduced numbers, immature phenotype) and defective Th1 differentiation in vivo; this phenotype cannot be compensated by IRF-1 alone, demonstrating that IRF-2 can act as a functional agonist of IRF-1 for a subset of ISRE-responsive genes.\",\n      \"method\": \"IRF-2 knockout mice, Leishmania major infection model, flow cytometric immune phenotyping\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined immune phenotypes and functional infection model\",\n      \"pmids\": [\"10934221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"IRF-2 functions as a negative regulator of the Cox-2 promoter: IRF-2-deficient macrophages show significantly increased basal and IFN-gamma-inducible Cox-2 expression; two IFN stimulation response elements in the mouse Cox-2 promoter bind endogenous IRF-2 and mediate repression.\",\n      \"method\": \"IRF-1/IRF-2 knockout macrophages, Cox-2 mRNA/protein quantification, EMSA, transient transfection reporter assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO macrophages combined with EMSA and promoter reporter assays with mutagenesis\",\n      \"pmids\": [\"10859338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IFN-gamma suppresses IL-4 gene expression through IRF-1 and IRF-2; both factors induced by IFN-gamma bind to three distinct sites in the IL-4 promoter and function as transcriptional repressors of IL-4.\",\n      \"method\": \"EMSA, chromatin immunoprecipitation, promoter reporter assays, IRF-1/IRF-2 overexpression in T cells\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA and reporter assays demonstrating direct binding and repression, single lab\",\n      \"pmids\": [\"12479817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"IRF-2 (DNA binding domain alone) and IRF-1 can co-occupy the IRF-E of the CIITA type IV promoter; the IRF-2 DNA binding domain is sufficient for cooperative transactivation with IRF-1 at this promoter, while the latent activation domain is required for autonomous IRF-2 transactivation.\",\n      \"method\": \"EMSA off-rate assays, deletion mutant reporter assays, co-occupancy DNA binding experiments\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical binding and functional reporter assays, single lab\",\n      \"pmids\": [\"12493643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Blimp-1, IRF-1, and IRF-2 bind with similar affinities to GAAAG-containing regulatory sites; Blimp-1, IRF-1, and IRF-2 all bind the IFN-beta promoter in vivo (by ChIP), and Blimp-1 inhibits IRF-1-dependent activation of IFN-beta promoter in cotransfections, suggesting competition with IRF-2 (and IRF-1) at shared sites.\",\n      \"method\": \"Binding competition assays, equilibrium dissociation constant measurement, ChIP, cotransfection reporter assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative binding assays plus in vivo ChIP, single lab\",\n      \"pmids\": [\"15494505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IRF-2 autonomously and cell-intrinsically functions as a negative regulator of basophil expansion; IRF-2-deficient mice exhibit STAT6-independent basophil expansion, and reduced basophil numbers (via Kit mutation) abolish spontaneous Th2 polarization, placing IRF-2 upstream of basophil-mediated Th2 control.\",\n      \"method\": \"IRF-2 knockout mice, genetic epistasis with Kit mutation, in vitro Th1/Th2 differentiation assays, basophil depletion/neutralization\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse with genetic epistasis and multiple functional assays demonstrating cell-intrinsic mechanism\",\n      \"pmids\": [\"15914553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IRF-2 physically interacts with RelA/p65 and recruits it into the nucleus; IRF-2 knockdown attenuates TNFα-induced NF-κB-dependent transcription by inhibiting nuclear localization of RelA, demonstrating that IRF-2 modulates NF-κB activity by controlling RelA subcellular localization.\",\n      \"method\": \"Co-immunoprecipitation, IRF-2 siRNA knockdown, NF-κB reporter assays, subcellular fractionation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single Co-IP plus functional reporter and localization data, single lab\",\n      \"pmids\": [\"18395009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IRF2 is sumoylated in vivo at three sites via the SUMO-E3 ligase PIASy; sumoylation does not affect IRF2 nuclear localization or DNA-binding activity, but increases its ability to repress IRF-1-mediated transcription and decreases its ability to activate ISRE and H4 promoters.\",\n      \"method\": \"Co-immunoprecipitation (IRF2/PIASy interaction), mutagenesis of sumoylation sites, in vivo sumoylation assay, reporter assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — sumoylation site mutagenesis with functional consequences, single lab\",\n      \"pmids\": [\"18514056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IRF-2 is a substrate of Mdm2 E3-ubiquitin ligase requiring dual-site interaction: one binding site in IRF-2 contacts the Mdm2 hydrophobic pocket and a second requires the Mdm2 acid domain; mutation of either site attenuates IRF-2 ubiquitination, and the Mdm2/IRF-2 complex forms in cells.\",\n      \"method\": \"Co-immunoprecipitation (Mdm2/IRF-2 complex in cells), in vitro ubiquitination assays, site-directed mutagenesis of IRF-2 binding sites\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in vitro ubiquitination assay with mutagenesis plus cellular co-IP, single study\",\n      \"pmids\": [\"19032150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IRF2 is required for homeostatic erythropoiesis: IRF2-null mice develop normocytic anemia with decreased late erythroblasts and increased apoptosis; this defect is rescued by additional knockout of IFNAR1, demonstrating that IRF2 maintains erythropoiesis by attenuating type I IFN signaling in erythroid progenitors.\",\n      \"method\": \"IRF-2 knockout mice, flow cytometric erythroid progenitor analysis, genetic epistasis (IFNAR1 double knockout rescue), apoptosis assays\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined cellular phenotype plus genetic epistasis rescue\",\n      \"pmids\": [\"18207304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IRF2-binding protein-1 (IRF2-BP1), which co-represses IRF2 transcriptional activity, also functions as a JDP2 ubiquitin E3 ligase via its RING-finger domain, enhancing JDP2 polyubiquitination and repressing ATF2-mediated transcription from CRE-containing promoters.\",\n      \"method\": \"Epitope-tag co-immunoprecipitation, in vitro ubiquitination assay, CRE reporter assays\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical ubiquitination assay and functional reporter assays, single lab\",\n      \"pmids\": [\"18671972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IRF2 occupies TLR3 and other IFN-inducible gene promoters in the unstimulated state and maintains basal expression, open chromatin structure, and active histone modifications (H3K9/K14 acetylation, H3K4 trimethylation); IRF2 also directly interacts with the BAF chromatin remodeling complex to maintain this primed state, while IRF1 drives rapid transcriptional activation upon stimulation.\",\n      \"method\": \"ChIP-seq/ChIP assays for IRF1, IRF2, histone marks; Co-immunoprecipitation with BAF complex; gene expression in IRF2 KO cells\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus Co-IP with BAF plus KO phenotype, single lab\",\n      \"pmids\": [\"25960866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IRF2 regulates the basal expression level of FAM111A transcriptionally; in a genome-wide siRNA screen, depletion of IRF2 enhanced replication of SPI-1-deleted orthopoxvirus, and this effect was found to be indirect through FAM111A (and the RFC complex), rather than direct antiviral activity by IRF2.\",\n      \"method\": \"Genome-wide siRNA screen, custom replication assays, microarray, quantitative RT-PCR, immunoblotting\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide screen with secondary validation and mechanistic follow-up, single lab\",\n      \"pmids\": [\"28320935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HCFC2 is required for binding of both IRF1 and IRF2 to the Tlr3 promoter; HCFC2 mutations abolish macrophage responses to poly(I:C) and impair survival during viral infections, placing HCFC2 as a required co-factor for IRF2-dependent Tlr3 transcription.\",\n      \"method\": \"ENU mutagenesis screen, ChIP for IRF1/IRF2 at Tlr3 promoter, macrophage functional assays, infection survival studies\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic screen plus ChIP binding assay, single lab\",\n      \"pmids\": [\"28970238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IRF2 directly binds a unique site in the GSDMD promoter to drive GSDMD transcription; IRF2-deficient macrophages show substantially reduced GSDMD expression, decreased IL-1β secretion, and inhibited pyroptosis; disruption of this single IRF2-binding site abolishes both canonical and non-canonical inflammasome signaling.\",\n      \"method\": \"ENU forward genetic screen, IRF2 KO macrophages, ChIP, promoter reporter assays with site-directed mutagenesis\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — forward genetic screen identified IRF2, confirmed by KO with multiple orthogonal methods including ChIP and promoter mutagenesis\",\n      \"pmids\": [\"31113851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IRF2 is identified by CRISPR genome-wide screen as required for caspase-4 expression and cytosolic LPS-mediated pyroptosis in human monocytes; IRF2 directly transcriptionally regulates caspase-4 (CASP4) levels; IFN-γ priming can compensate IRF2 deficiency through IRF1 induction.\",\n      \"method\": \"Genome-wide CRISPR/Cas9 screen, IRF2 KO in human monocytes and iPSC-derived monocytes, CASP4 expression analysis, bacterial infection assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide unbiased screen with orthogonal KO validation in multiple cell types\",\n      \"pmids\": [\"31353801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IRF2 loss of function (identified by CRISPR screen) leads to reduced MHC class I antigen presentation by decreasing transcription of immunoproteasome components, TAP, and ERAP1, and simultaneously increases PD-L1 expression; IRF2 thus acts as a transcriptional activator of MHC-I pathway genes and a repressor of PD-L1.\",\n      \"method\": \"CRISPR forward genetic screen, IRF2 KO in HeLa and tumor cells, MHC-I antigen presentation assays, gene expression profiling\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — unbiased CRISPR screen plus mechanistic follow-up with multiple defined pathway readouts\",\n      \"pmids\": [\"31471524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"KRAS* represses IRF2 expression, which in turn directly represses CXCL3 transcription; KRAS*-mediated loss of IRF2 causes high CXCL3 expression that drives MDSC migration to tumors via CXCR2, promoting immune evasion.\",\n      \"method\": \"Enforced IRF2 expression rescue experiments, CXCR2 inhibition, tumor microenvironment immune cell analysis\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic axis validated by rescue (enforced IRF2 expression) and pharmacological inhibition, single lab\",\n      \"pmids\": [\"30905761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IRF-2 overexpression down-regulates IFN-γ-induced PD-L1 promoter activity and protein levels in HCC cells in a dose-dependent manner; two functional IRF-1 response elements (IRE1 and IRE2) in the PD-L1 (CD274) promoter are bound by both IRF-1 and IRF-2, with IRF-2 antagonizing IRF-1-mediated PD-L1 activation.\",\n      \"method\": \"IRF-2 overexpression, PD-L1 promoter reporter assays, site-directed mutagenesis of IREs, IFN-γ stimulation assays\",\n      \"journal\": \"Cancer immunology, immunotherapy : CII\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter mutagenesis with functional reporter assays, single lab\",\n      \"pmids\": [\"32377817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IRF2 is a master regulator of human keratinocyte stem cell fate: CRISPR knockdown of IRF2 in keratinocytes with low stem cell potential increases self-renewal, migration, and epidermis formation; IRF2 binds and regulates active cis-regulatory elements at interferon response and antigen presentation genes in keratinocytes.\",\n      \"method\": \"Chromatin profiling, transcriptional profiling, CRISPR-KD, keratinocyte functional assays (self-renewal, migration, epidermis formation)\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — integrated chromatin/transcriptional profiling plus CRISPR-KD with functional readouts, single lab\",\n      \"pmids\": [\"31611556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Conditional deletion of Irf2 in intestinal epithelium causes premature differentiation of colonic stem cells (CoSCs) into transit-amplifying cells, reducing CoSC numbers and organoid-forming potential; this phenotype is phenocopied by repeated poly(I:C) injections in wild-type mice, demonstrating that IRF2 maintains colonic stem cell stemness by attenuating chronic type I IFN signaling.\",\n      \"method\": \"Conditional Irf2 knockout mice (Irf2ΔIEC), DSS colitis model, organoid assays, poly(I:C) injection epistasis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with defined stem cell phenotype plus phenocopy by IFN induction establishing the mechanism\",\n      \"pmids\": [\"32901054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IRF2 directly binds the GSDMD promoter to drive GSDMD transcription in cardiomyocytes; IRF2 silencing in hypoxia-treated H9c2 cells decreases GSDMD, GSDMD-N, and cleaved caspase-1 levels and reduces IL-1β and IL-18, confirming IRF2 as a transcriptional regulator of pyroptosis in myocardial infarction.\",\n      \"method\": \"Chromatin immunoprecipitation, dual luciferase reporter assay, IRF2 siRNA knockdown in H9c2 cells, in vivo MI model with IRF2 silencing\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assay confirming direct GSDMD promoter binding, consistent with PMID 31113851, single lab\",\n      \"pmids\": [\"34878155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IRF2 directly transcriptionally activates CENP-N expression in NPC cells (confirmed by ChIP and dual luciferase assays); the IRF2/CENP-N/AKT axis promotes aerobic glycolysis, proliferation, cell cycling, and apoptosis resistance; CENP-N forms a complex with AKT (confirmed by immunoprecipitation and GST pulldown).\",\n      \"method\": \"ChIP, dual luciferase reporter assay, immunoprecipitation, GST pulldown, CENP-N KD/OE with phenotypic assays\",\n      \"journal\": \"Journal of experimental & clinical cancer research : CR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding confirmed by ChIP and reporter assay plus protein complex by pulldown, single lab\",\n      \"pmids\": [\"34893086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IRF2 transcriptionally activates INPP4B in AML cells by binding its promoter; IRF2-driven INPP4B expression promotes autophagy and suppresses apoptosis; restoration of INPP4B blocks the pro-apoptotic effects of IRF2 knockdown.\",\n      \"method\": \"IRF2 overexpression/knockdown, INPP4B rescue experiments, autophagy markers (LC3-I/II, Beclin-1, p62), colony formation, apoptosis assays\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic rescue experiments establishing epistatic relationship, single lab\",\n      \"pmids\": [\"28579269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CD8+ T cell-specific deletion of IRF2 prevents acquisition of the T cell exhaustion transcriptional program within tumors, enabling sustained effector functions; sustained antitumor control by IRF2-deficient CD8+ T cells requires continuous integration of both type I and type II IFN signals, establishing IRF2 as a feedback molecule that converts IFN signals into T cell suppression.\",\n      \"method\": \"CD8+ T cell-specific IRF2 conditional knockout, tumor models, adoptive cell therapy, immune checkpoint therapy, transcriptional profiling\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional KO with mechanistic IFN epistasis experiments and multiple functional readouts\",\n      \"pmids\": [\"36370712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IRF2 is required cell-intrinsically for development of Ly6Clo (nonclassical) monocytes; NOTCH2/DLL1-induced transition of Ly6Chi to Ly6Clo monocytes requires IRF2, placing IRF2 downstream of NOTCH2 in a transcriptional hierarchy controlling nonclassical monocyte fate.\",\n      \"method\": \"IRF2 conditional deletion in myeloid progenitors, in vitro DLL1-induced monocyte transition assay, genetic epistasis with BCL6 and NUR77\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined developmental phenotype and in vitro epistasis, single lab\",\n      \"pmids\": [\"37607223\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IRF2 is a winged helix-turn-helix transcription factor that binds AAGTGA hexamer repeats in IFN and IFN-inducible gene promoters using its N-terminal DNA-binding domain, where it predominantly acts as a transcriptional repressor by competing with the activator IRF1 and exerting silencing via a C-terminal repression domain; it is regulated post-translationally by phosphorylation (by PKA, PKC, CK2), sumoylation (by PIASy, increasing repressor activity), and ubiquitination (by Mdm2, requiring dual-site docking); beyond repressing IFN-stimulated genes, IRF2 directly activates transcription of GSDMD and CASP4 (enabling pyroptosis), histone H4 genes (linking it to cell-cycle progression at G1/S), MHC-I pathway components, and INPP4B; it attenuates type I IFN signaling to maintain erythroid, hematopoietic, intestinal epithelial, and keratinocyte stem cell homeostasis; recruits RelA/p65 to the nucleus to modulate NF-κB activity; cooperates with HCFC2 and the BAF chromatin remodeling complex for chromatin-level regulation of IFN-inducible promoters; and in CD8+ T cells, redirects sustained IFN signals into an exhaustion program that suppresses antitumor immunity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"IRF2 is a winged helix-turn-helix transcription factor that binds AAGTGA hexamer repeats in interferon (IFN) and IFN-inducible gene promoters, where its founding role is to antagonize the activator IRF-1 at shared cis-elements both by competitive occupancy and by active silencing through a C-terminal repression domain [#0, #1, #3, #8]. As an in vivo negative regulator of type I IFN gene induction, IRF2 restrains IFN-alpha/beta-driven transcription to preserve tissue homeostasis: its loss causes hematopoietic and B-lymphopoietic suppression, normocytic anemia, CD8+ T cell hyper-responsiveness and inflammatory skin disease, and depletion of colonic and keratinocyte stem cell pools — phenotypes rescued or phenocopied by manipulating IFN signaling [#2, #10, #20, #30, #31]. IRF2 is not merely a passive antagonist: it acts as a direct transcriptional activator of histone H4 genes at the G1/S transition, controlling cell-cycle-regulated gene expression [#5, #7], and directly drives transcription of the pyroptosis effectors GSDMD and caspase-4 (CASP4), licensing canonical and non-canonical inflammasome signaling and IL-1beta release [#25, #26, #32]. It also activates the MHC class I antigen-presentation machinery (immunoproteasome components, TAP, ERAP1) while repressing PD-L1, coupling IRF2 to tumor immune visibility [#27, #29]. IRF2 maintains a primed chromatin state at IFN-inducible promoters such as TLR3 — sustaining basal expression, open chromatin, and active histone marks — through cooperation with the BAF remodeling complex and the cofactor HCFC2 [#22, #24]. In CD8+ T cells, IRF2 converts sustained type I and type II IFN signals into an exhaustion program, and its deletion preserves effector function and antitumor control [#35]. IRF2 activity is tuned post-translationally by serine phosphorylation (PKA, PKC, CK2), PIASy-mediated sumoylation that enhances repressor and weakens activator function, and Mdm2-dependent ubiquitination requiring dual-site docking [#9, #18, #19].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Established the foundational identity of IRF2: a transcription factor sharing IRF-1's DNA targets but opposing its activity, defining the competitive antagonism model that frames all later work.\",\n      \"evidence\": \"cDNA cloning with DNA-binding and transcriptional reporter assays\",\n      \"pmids\": [\"2475256\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the structural basis of binding or the domain mediating repression\", \"Did not address in vivo physiological role\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Resolved whether the antagonism arises from shared DNA recognition by showing IRF-1 and IRF-2 select indistinguishable AAGTGA hexamer repeats, and demonstrated in vivo that IRF-2 normally attenuates type I IFN induction.\",\n      \"evidence\": \"SELEX/EMSA binding-site selection plus IRF-2 knockout mice with NDV infection and hematopoietic phenotyping\",\n      \"pmids\": [\"7687740\", \"8402903\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not explain how identical binding produces opposite transcriptional outputs\", \"Hematopoietic suppression mechanism not yet tied to IFN signaling\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Mapped the molecular basis of repression to a discrete C-terminal repression domain plus a latent central activation domain, and identified an IRF-1-driven autoregulatory loop controlling IRF-2 expression.\",\n      \"evidence\": \"LexA fusion reporters, truncation analysis, promoter deletion/reporter assays, FISH mapping\",\n      \"pmids\": [\"8152803\", \"7507207\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab domain mapping\", \"Identity of silencing partners recruited by the repression domain unknown\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Reframed IRF2 as a bona fide activator, not just an antagonist, by purifying it as the histone H4 cell-cycle-element factor HiNF-M and showing direct activation of H4 transcription, and located its oncogenic activity to the N-terminal DNA-binding/repression domain.\",\n      \"evidence\": \"Protein purification, EMSA, reconstituted activation assays; deletion mutants with focus formation and nude mouse tumor assays\",\n      \"pmids\": [\"7566094\", \"7630638\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a single domain mediates both repression and transformation not resolved\", \"Activator vs repressor context-switch not mechanistically defined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Began defining post-translational control of IRF2 by showing it is phosphorylated on serines by PKA, PKC, and CK2 but not MAP kinases.\",\n      \"evidence\": \"32P metabolic labeling, in vitro kinase assays, 2D phosphopeptide and phosphoamino acid analysis\",\n      \"pmids\": [\"9213219\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of phosphorylation on activity not established\", \"Single-lab characterization\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Solidified IRF2 as an active cell-cycle regulator via knockout-plus-rescue showing it is required for cell-cycle-regulated H4 transcription, and defined its fold as a winged helix-turn-helix making the structural basis of hexamer recognition explicit.\",\n      \"evidence\": \"IRF-2 KO fibroblasts with synchronized cell-cycle analysis and re-expression rescue; NMR structure with DNA-contact mapping\",\n      \"pmids\": [\"9417064\", \"9562558\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of full-length protein or DNA co-complex not determined\", \"E2F-independent regulatory logic incompletely defined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Connected IRF2 loss-of-function phenotypes directly to dysregulated IFN-alpha/beta signaling through epistasis, and revealed context-dependent agonist behavior, while extending its repressor reach to the Cox-2 promoter.\",\n      \"evidence\": \"IRF-2 KO mice with IFNAR nullizygosity rescue; Leishmania infection model and NK/Th1 phenotyping; KO macrophages with EMSA and Cox-2 promoter reporters\",\n      \"pmids\": [\"11114377\", \"10934221\", \"10859338\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of agonist vs antagonist switching not defined\", \"Direct vs indirect targets in immune cells not fully separated\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Extended IRF2-mediated repression to T-helper cytokine control, showing IRF-1 and IRF-2 repress the IL-4 promoter downstream of IFN-gamma.\",\n      \"evidence\": \"EMSA, ChIP, promoter reporters with IRF overexpression in T cells\",\n      \"pmids\": [\"12479817\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab evidence\", \"Relative contribution of IRF-1 versus IRF-2 not resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined how the IRF2 DNA-binding domain can cooperate with IRF-1, showing co-occupancy and DBD-sufficient cooperative transactivation at CIITA while autonomous activation requires the latent activation domain.\",\n      \"evidence\": \"EMSA off-rate, co-occupancy binding, and deletion-mutant reporter assays\",\n      \"pmids\": [\"12493643\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Promoter features dictating cooperation vs competition unknown\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Placed IRF2 within a broader competition network at IFN-beta by showing Blimp-1 shares its GAAAG sites and competes for occupancy.\",\n      \"evidence\": \"Quantitative binding competition, ChIP, cotransfection reporters\",\n      \"pmids\": [\"15494505\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct IRF-2 vs Blimp-1 displacement not isolated\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Greatly expanded IRF2 regulation and partnerships: defined PIASy-dependent sumoylation enhancing repression, Mdm2-mediated ubiquitination requiring dual-site docking, physical recruitment of RelA/p65 to the nucleus, and a requirement for IRF2 in erythropoiesis via IFN-signaling attenuation.\",\n      \"evidence\": \"Co-IP, in vivo sumoylation and site mutagenesis, in vitro ubiquitination with mutagenesis, siRNA with NF-kB reporters/fractionation, KO mice with IFNAR1 double-knockout rescue\",\n      \"pmids\": [\"18514056\", \"19032150\", \"18395009\", \"18207304\", \"18671972\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RelA recruitment rests on single Co-IP without reciprocal validation\", \"How PTMs are integrated to set activator/repressor balance unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined the chromatin-level mechanism of IRF2 priming: it occupies IFN-inducible promoters in the resting state, maintains open chromatin and active histone marks, and physically engages the BAF remodeling complex.\",\n      \"evidence\": \"ChIP/ChIP-seq for IRF1/IRF2 and histone marks, Co-IP with BAF, IRF2 KO expression analysis\",\n      \"pmids\": [\"25960866\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"BAF interaction not reciprocally validated\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified a required cofactor (HCFC2) for IRF2 promoter binding at Tlr3 and showed an antiviral phenotype that is indirect, acting through transcriptional control of FAM111A rather than intrinsic IRF2 antiviral activity.\",\n      \"evidence\": \"ENU and genome-wide siRNA screens with ChIP, replication assays, and expression analysis\",\n      \"pmids\": [\"28970238\", \"28320935\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Biochemical nature of the IRF2-HCFC2 interaction not defined\", \"Direct vs indirect target distinction relies on a single screen lineage\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established IRF2 as a direct transcriptional activator of multiple effector programs identified by unbiased screens: GSDMD and CASP4 for pyroptosis, the MHC-I antigen-presentation machinery with PD-L1 repression, and stem-cell/tumor-microenvironment control via keratinocyte fate and the KRAS*-IRF2-CXCL3 axis.\",\n      \"evidence\": \"ENU and CRISPR forward genetic screens, KO in macrophages/monocytes/HeLa/tumor cells, ChIP and promoter mutagenesis, chromatin/transcriptional profiling, rescue and CXCR2 inhibition\",\n      \"pmids\": [\"31113851\", \"31353801\", \"31471524\", \"30905761\", \"31611556\", \"32377817\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism selecting activation vs repression at each target promoter not defined\", \"Cofactor requirements for direct activation incompletely mapped\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated in vivo that IRF2 maintains colonic stem cell stemness specifically by buffering chronic type I IFN signaling, with conditional deletion phenocopied by poly(I:C).\",\n      \"evidence\": \"Intestinal-epithelium conditional Irf2 KO, organoid assays, DSS colitis, poly(I:C) phenocopy\",\n      \"pmids\": [\"32901054\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct IRF2 target genes in stem cells not enumerated\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Broadened IRF2's direct activator repertoire to additional disease-relevant targets, confirming GSDMD-driven cardiomyocyte pyroptosis and identifying CENP-N (in NPC) and INPP4B (in AML) as direct transcriptional targets driving proliferation, glycolysis, autophagy, and apoptosis resistance.\",\n      \"evidence\": \"ChIP, dual-luciferase reporters, knockdown/overexpression and rescue with phenotypic assays in cardiomyocyte, NPC, and AML models\",\n      \"pmids\": [\"34878155\", \"34893086\", \"28579269\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Each axis validated in a single lab/cell context\", \"Tissue-specificity of target selection not explained\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined IRF2 as the feedback molecule that converts sustained type I and II IFN signaling into the CD8+ T cell exhaustion program, with cell-intrinsic deletion preserving effector function and antitumor control.\",\n      \"evidence\": \"CD8+ T cell-specific conditional KO, tumor and adoptive-transfer models, checkpoint therapy, IFN epistasis, transcriptional profiling\",\n      \"pmids\": [\"36370712\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct exhaustion-program target genes bound by IRF2 not fully mapped\", \"Translational relevance to human T cells not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Positioned IRF2 in a developmental transcriptional hierarchy by showing it is required cell-intrinsically downstream of NOTCH2 for nonclassical Ly6Clo monocyte differentiation.\",\n      \"evidence\": \"Myeloid-progenitor conditional deletion, DLL1-induced transition assay, epistasis with BCL6 and NUR77\",\n      \"pmids\": [\"37607223\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct IRF2 targets in the NOTCH2 pathway unknown\", \"Single-lab study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"What molecular features at a given promoter switch IRF2 between active repressor and direct activator, and how its PTM code (phosphorylation, sumoylation, ubiquitination) integrates with cofactors (BAF, HCFC2) to set this balance, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking PTM state to activator/repressor switching\", \"No structure of IRF2 in complex with cofactors or at activated vs repressed promoters\", \"Determinants of tissue-specific target gene selection unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 3, 5, 25, 26, 27]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 8]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [17, 18]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 10, 25, 26, 27, 35]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 3, 5, 25, 27]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [5, 7]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [25, 26, 32]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"IRF1\", \"RELA\", \"MDM2\", \"PIAS4\", \"HCFC2\", \"SMARCA4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}